Top Prefered Companies To Buy Right Now

Forbes Dividend Investor subscribers received this hotline on July 29, 2013.

iron (Photo credit: Wikipedia)

Slowing growth in China and a grinding recession in Europe have depressed prices of steel as well as the ingredients used to make it, namely metallurgical coal and iron ore. Unfortunately for Brazilian mining giant Vale Vale, it produces both of them and its shares have been pounded down to their lowest levels since 2009.

Since February of this year, iron ore prices have fallen 26% from $155 per dry metric ton down to $115. Despite the steep drop, higher prices for steel in recent weeks suggest that iron ore could be due for a bounce, too. Prices in China for hot-rolled steel band are up $11 per ton to $492 in the past two weeks. World export prices rose $12 to $546 per ton.

10 Best Gold Stocks To Buy For 2015: Xinyuan Real Estate Co Ltd(XIN)

Xinyuan Real Estate Co. Ltd., together with its subsidiaries, engages in residential real estate development in China. The company?s residential projects comprise various residential buildings that include multi-layer apartment buildings, sub-high-rise apartment buildings, or high-rise apartment buildings; auxiliary services and amenities, such as retail outlets, leisure and health facilities, kindergartens, and schools; and small scale residential properties. It also offers property management and other real estate related services, such as landscaping and installing intercom systems. In addition, the company leases properties, including an elementary school, a basement, three clubhouses, five kindergartens, and parking facilities. As of December 31, 2010, it had 21 completed projects with a total gross floor area (GFA) of approximately 2,049,460 square meters and comprising a total of 23,324 units, as well as 8 projects under construction with a total GFA of 1,804,946 sq uare meters. It primarily operates in seven tier II cities, comprising Hefei, Jinan, Kunshan, Suzhou, Zhengzhou, Xuzhou, and Chengdu. The company was founded in 1997 and is headquartered in Beijing, the People?s Republic of China.

Advisors' Opinion:

• [By Tim Brugger]

  Having completed the repurchase of approximately $12.6 million of the $20 million share buyback program started last year, Xinjuan Real Estate's (NYSE: XIN  ) board of directors has authorized the repurchase of an additional $60 million of outstanding stock, the company announced today.

• [By Benjamin Shepherd]

  In the meantime though, I would avoid betting on a hard Chinese landing, a bet that has cost many investors dearly over the past few years. I would, however, avoid most of the leading Chinese real estate developers such as China Vanke (OTC: CVKEF) and Xinyuan Real Estate (NYSE: XIN) which are almost entirely dependent on the domestic markets.

Top Prefered Companies To Buy Right Now: Cinedigm Digital Cinema Corp(CIDM)

Cinedigm Digital Cinema Corp. provides technology solutions, financial advice and guidance, and software services to content owners and distributors, and movie exhibitors in the United States. The company engages in the ownership and licensing of digital systems to theatrical exhibitors; and provides monitoring, billing, collection, verification, and other management services to the company?s Phase I Deployment and Phase II Deployment, as well as to exhibitors, who purchase their own equipment. It also develops and licenses software to the theatrical distribution and exhibition industries; and provides applications service provider service, and software enhancements and consulting services. In addition, the company distributes movie features, trailers, and other alternative content to movie theaters and other venues with digital cinema equipment through satellite, hard drives, and broadband; and provides non-theatrical satellite based distribution of content into various out of home networks and other channels. Further, it provides content marketing and distribution services to alternative and theatrical content owners, and theatrical exhibitors, as well as offers in-theatre advertising services. The company was formerly known as Access Integrated Technologies, Inc. and changed its name to Cinedigm Digital Cinema Corp. in October 2009. Cinedigm Digital Cinema Corp. was founded in 2000 and is headquartered in Morristown, New Jersey.

Advisors' Opinion:

• [By Wallace Witkowski]

  Cinedigm Corp. (CIDM) �retreated 10% to $2.84 on light volume after the media-content distributor said it was launching an unspecified secondary offering of its Class A shares.

• [By Monica Gerson]

  Cinedigm (NASDAQ: CIDM) slipped 14.87% to $2.69 after the company announced a proposed public offering of common stock.

  Walter Energy (NYSE: WLT) shares tumbled 12.98% to $7.91 after the company priced $200 million of 9.5% Senior Secured Notes and $350 million of Senior Secured Second Lien PIK Toggle Notes.

Top Prefered Companies To Buy Right Now: USG Corporation(USG)

USG Corporation, through its subsidiaries, engages in the manufacture and distribution of building materials worldwide. The company offers gypsum and related products, including gypsum wallboard, joint compounds used for finishing wallboard joints, cement boards, glass mat sheathing, gypsum fiber panels, poured gypsum underlayments, ultra light panels, and various construction plaster products. Its gypsum products are used in various building applications to finish the interior walls, ceilings, and floors in residential, commercial, and institutional constructions, and repair and remodel constructions. The company also produces gypsum-based products for agricultural and industrial customers to use in various applications, including soil conditioning, road repair, fireproofing, and ceramics. In addition, it manufactures ceiling grid and acoustical ceiling tile for electrical and mechanical systems, and air distribution and maintenance applications. USG Corporation distribut es its gypsum products through specialty wallboard distributors, building materials dealers, home improvement centers and other retailers, contractors, and a network of distributors. Further, it distributes other manufacturers? gypsum wallboard, joint compound and other gypsum products, as well as drywall metal, insulation, and roofing products and accessories. The company sells its products under SHEETROCK, DUROCK, FIBEROCK, SECUROCK, LEVELROCK, RED TOP, IMPERIAL, DIAMOND, SUPREMO, AURATONE, ACOUSTONE, DONN, DX, FINELINE, CENTRICITEE, CURVATURA, and COMPASSO brands. The company was founded in 1901 and is based in Chicago, Illinois.

Advisors' Opinion:

• [By Holly LaFon]

  Pimco managing director Mark Kiesel mentions Whirlpool (WHR), Weyerhaeuser (WY), USG (USG), Toll Brothers (TOLL) and KB Home (KBH) as good plays on housing:�

• [By Seth Jayson]

  USG (NYSE: USG  ) reported earnings on April 24. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), USG missed estimates on revenues and missed estimates on earnings per share.

Top Prefered Companies To Buy Right Now: ChemoCentryx Inc (CCXI)

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.

The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).

The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.

CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.

CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).

The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.

Advisors' Opinion:

• [By James E. Brumley]

  The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.

• [By CRWE]

  ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.

Top Prefered Companies To Buy Right Now: Hasbro Inc.(HAS)

Hasbro, Inc. engages in the design, manufacture, and marketing of games and toys. The company principally provides children?s and family leisure time and entertainment products and services. It offers various games, including traditional board, card, hand-held electronic, trading card, roleplaying, and DVD games, as well as electronic learning aids and puzzles. Hasbro?s toy products include boy?s action figures, vehicles and playsets, girl?s toys, electronic toys, plush products, preschool toys and infant products, electronic interactive products, creative play products, and toy related specialty products. The company also licenses certain of its trademarks, characters, and other property rights to third parties for use in connection with consumer promotions and for the sale of noncompeting toys and games, and non-toy products. It offers its products primarily under PLAYSKOOL, TRANSFORMERS, NERF, MY LITTLE PONY, LITTLEST PET SHOP, TONKA, G.I. JOE, SUPER SOAKER, MILTON BRAD LEY, PARKER BROTHERS, CRANIUM, AVALON HILL, TIGER, FURREAL FRIENDS, BABY ALIVE, STRAWBERRY SHORTCAKE, and WIZARDS OF THE COAST brand names. The company markets its products to various customers, including wholesalers, distributors, chain stores, discount stores, mail order houses, catalog stores, department stores, and other retailers, as well as Internet-based e-tailers. It has a strategic licensing agreement with Electronic Arts Inc. (EA), which provides EA with the worldwide rights to create digital games for various platforms, including mobile phones, personal computers, and game consoles, as well as; and a strategic relationship with Universal Pictures to produce approximately three motion pictures based on certain of company?s brands. Hasbro sells its products through its own sales force and distributors primarily in the United States, Canada, Mexico, Europe, the Asia Pacific, Latin America, and South America. The company was founded in 1923 and is headquartered in Paw tucket, Rhode Island.

Advisors' Opinion:

• [By Matt Egan]

  There are also a long line of non-tech consumer companies slated to release results this week like Chipotle (CMG), Coca-Cola, Hasbro (HAS), McDonald's and Six Flags (SIX). An update on the pivotal auto market is also on tap in the form of earnings reports from both Ford (F) and General Motors.

Top Prefered Companies To Buy Right Now: Ku6 Media Co. Ltd.(KUTV)

Ku6 Media Co., Ltd. operates as an online video company in the People?s Republic of China. It operates ku6.com, an online video portal that provides news, reports, and other interactive entertainment programs for its users, as well as offers a video platform for sharing and watching user-generated content. The company also operates juchang.com that provides copyrighted content, such as movies, television series, and other video programs sourced from its content partners. In addition, it offers Internet audio solutions, including online radio channels, built-in radio for online games, and other services to customers through its online audio advertising business. The company is based in Beijing, China.

Advisors' Opinion:

• [By Bryan Murphy]

  There's little doubt that merely suggesting it will enflame some traders, but truth is truth - Ku6 Media Co Ltd (NASDAQ:KUTV) is overbought and ripe for a pullback, soon. Anyone worried about not having a place to park those proceeds, however, need not fret. There's a brand new breakout finally underway that still has plenty of proverbial meat on the bone... Star Scientific, Inc. (NASDAQ:STSI), which just blasted past a key resistance line around $2.11 today. In so doing, it became free to rally without restraint.

• [By John Udovich]

  Small cap video technology stocks Envivio Inc (NASDAQ: ENVI), Ku6 Media Co Ltd (NASDAQ: KUTV) and Tremor Video Inc (NYSE: TRMR) made some interesting moves today and in recent days or months���meaning its worth taking a closer look at all three to see if there might be opportunities for traders and investors alike:

• [By Jake L'Ecuyer]

  Technology sector was the leading decliner in the US market today. Top losers in the sector included Constant Contact (NASDAQ: CTCT), off 8.1 percent, and Ku6 Media Co (NASDAQ: KUTV), down 9.1 percent.

• [By Jake L'Ecuyer]

  Tech sector was the leading decliner in the US market today. Among the sector stocks, Bitauto Holdings (NYSE: BITA) was down more than 8.6 percent, while Ku6 Media Co (NASDAQ: KUTV) tumbled around 8.4 percent.

Top Prefered Companies To Buy Right Now: Rollins Inc. (ROL)

Rollins, Inc., through its subsidiaries, provides pest and termite control services to residential and commercial customers in North America. It offers pest control services, and protection against termite damage, rodents, and insects to homes and businesses, including hotels, food service establishments, food manufacturers, retailers, and transportation companies. The company also provides pest management and sanitation services and products to the food and commodity industries. It operates under the brand names of Orkin and PCO Services brand names, as well as under the Acurid service mark. The company also offers its services in Central America, the Caribbean, the Middle East, Asia, the Mediterranean, and Europe. As of December 31, 2010, it had 56 domestic franchises and 16 international franchises. The company, formerly known as Rollins Broadcasting, Inc., was founded in 1948 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:

• [By Alex Planes]

  A new kind of buyout
  The first leveraged buyout in American history �took place on June 19, 1964, when Rollins Broadcasting (NYSE: ROL  ) made a $62.4 million bid to acquire nationwide exterminator Orkin. The deal, later called "Jonah swallowing the whale" by BusinessWeek, saw a company with $7.9 million in annual revenue and $600,000 in annual net income put up virtually none of its own money to acquire a company with $37.3 million in annual revenue and $3 million in annual net income. Rollins/Orkin (the pairing has worked out for nearly five decades) quotes the particulars of the deal on its website: